三种局部糖皮质激素注射治疗葡萄膜炎性黄斑水肿的随机对照试验
POINT试验为多中心随机临床试验,将葡萄膜炎性黄斑水肿患者按1:1:1随机分配至球周曲安奈德(PTA)、玻璃体腔曲安奈德(ITA)或玻璃体腔地塞米松植入剂(IDI)治疗。8周时三组黄斑中心凹下厚度(CST)较基线分别下降23%、39%和46%,ITA与IDI在改善水肿和视力方面均优于PTA,但眼压≥24 mmHg风险更高。
要点
- 8周时ITA与IDI降低CST的幅度均优于PTA,IDI不劣于ITA。
- ITA与IDI在改善和消退黄斑水肿方面均优于PTA。
- 玻璃体腔注射组眼压≥24 mmHg风险高于球周组,两种玻璃体腔治疗间无显著差异。
核心结论
- 玻璃体腔曲安奈德与玻璃体腔地塞米松植入剂治疗葡萄膜炎性黄斑水肿均优于球周曲安奈德,但眼压升高风险轻度增加。
研究设计与样本
- 多中心随机临床试验,葡萄膜炎性黄斑水肿患者按1:1:1随机接受PTA、ITA或IDI治疗,双眼患病者双眼接受同一治疗。
主要发现
- 8周时CST相对基线比例分别为0.77、0.61、0.54,对应下降23%、39%、46%(PTA、ITA、IDI)。
- ITA与PTA比较的HR为0.79(99.87%CI 0.65-0.96),IDI与PTA比较的HR为0.69(99.87%CI 0.56-0.86),P<0.0001。
- IDI相对ITA的HR为0.88(99.87%CI 0.71-1.08),8周时非劣于ITA。
- 8周时ITA与IDI组BCVA改善较PTA组多5个字母(P<0.004)。
关键数值与推荐
- 眼压≥24 mmHg风险:ITA相对球周组HR 1.83(95%CI 0.91-3.65),IDI相对球周组HR 2.52(95%CI 1.29-4.91)。
- 两种玻璃体腔治疗组之间眼压事件风险无显著差异。
临床怎么用
- 对葡萄膜炎性黄斑水肿可优先考虑玻璃体腔曲安奈德或地塞米松植入剂以更有效减轻水肿和改善视力,同时需监测眼压升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the comparative effectiveness of 3 regional corticosteroid injections for uveitic macular edema (ME): periocular triamcinolone acetonide (PTA), intravitreal triamcinolone acetonide (ITA), and the intravitreal dexamethasone implant (IDI). DESIGN: Multicenter, randomized clinical trial. PARTICIPANTS: Patients with uveitic ME. METHODS: Patients were randomized 1:1:1 to receive 1 of the 3 therapies. Patients with bilateral ME were assigned the same treatment for both eyes. MAIN OUTCOME MEASURES: The primary outcome was the proportion of baseline (PropBL) central subfield thickness (CST) at 8 weeks (CST at 8 weeks/CST at baseline) assessed with OCT by masked readers. Secondary outcomes included ≥20% improvement and resolution of ME, best-corrected visual acuity (BCVA), and intraocular pressure (IOP) events over 24 weeks. RESULTS: All treatment groups demonstrated improved CST during follow-up. At 8 weeks, each group had clinically meaningful reductions in CST relative to baseline (PropBL: 0.77, 0.61, and 0.54, respectively, which translates to reductions of 23%, 39%, and 46% for PTA, ITA, and IDI, respectively). Intravitreal triamcinolone acetonide (PropBL ITA/PropBL PTA, hazard ratio [HR], 0.79; 99.87% confidence interval [CI], 0.65-0.96) and IDI (PropBL IDI/PropBL PTA, HR, 0.69; 99.87% CI, 0.56-0.86) had larger reductions in CST than PTA (P < 0.0001). Intravitreal dexamethasone implant was noninferior to ITA at 8 weeks (PropBL IDI/PropBL ITA, HR, 0.88; 99.87% CI, 0.71-1.08). Both ITA and IDI treatments also were superior to PTA treatment in improving and resolving uveitic ME. All treatment groups demonstrated BCVA improvement throughout follow-up. Both ITA and IDI groups had improvements in BCVA that was 5 letters greater than in the PTA group at 8 weeks (P < 0.004). The risk of having IOP ≥24 mmHg was higher in the intravitreal treatment groups compared with the periocular group (HR, 1.83; 95% CI, 0.91-3.65 and HR, 2.52; 95% CI, 1.29-4.91 for ITA and IDI, respectively); however, there was no significant difference between the 2 intravitreal treatment groups. CONCLUSIONS: Intravitreal triamcinolone acetonide and the IDI were superior to PTA for treating uveitic ME with modest increases in the risk of IOP elevation. This risk did not differ significantly between intravitreal treatments.
引用
- Thorne JE, Sugar EA, Holbrook JT, et al. Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial. Ophthalmology. 2018. PMID: 30269924. doi:10.1016/j.ophtha.2018.08.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。